Clinical and economic implications of topical cyclosporin A for the treatment of dry eye.

Abstract

The purpose of this study was to investigate clinical, economic, and patient-reported outcomes related to topical cyclosporin A for the treatment of dry eye. The medical records of 181 patients with dry eye were reviewed (mean age, 67.6 yr; 72% women) for up to two years (average follow-up, 1.34 yr) before and after treatment with cyclosporin A 0.05% ophthalmic solution administered topically twice daily. Corneal staining, average discomfort scores, and patient satisfaction markedly improved, whereas the number of prescriptions for ancillary medications and dry eye-related visits to the ophthalmologist declined significantly during the treatment period. In a naturalistic clinical setting, topical cyclosporin A therapy improved the signs and symptoms of dry eye disease, resulting in high patient satisfaction, fewer patients with chronic dry eye visiting the ophthalmologist, and less ancillary drug use.

• Authors: Warren D Cross, Luis F Lay Jr, John G Walt, Chris M Kozma
• Journal: Managed care interface (Manag Care Interface) Vol. 15 Issue 9 Pg. 44-9 (Sep 2002) ISSN: 1096-5645 [Print] United States
• PMID: 12244650 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunosuppressive Agents
• Cyclosporine

Topics

• Administration, Topical
• Aged
• Cyclosporine (administration & dosage, economics, therapeutic use)
• Dry Eye Syndromes (drug therapy, economics)
• Female
• Humans
• Immunosuppressive Agents (administration & dosage, economics, therapeutic use)
• Male
• Middle Aged
• Patient Satisfaction
• United States